Neutrophil-to-lymphocyte ratio and C-reactive protein-to-albumin ratio as prognostic factors for unresectable advanced or recurrent gastric cancer

被引:10
作者
Namikawa, Tsutomu [1 ]
Shimizu, Shigeto [1 ]
Yokota, Keiichiro [1 ]
Tanioka, Nobuhisa [1 ]
Munekage, Masaya [1 ]
Uemura, Sunao [1 ]
Maeda, Hiromichi [2 ]
Kitagawa, Hiroyuki [1 ]
Kobayashi, Michiya [2 ]
Hanazaki, Kazuhiro [1 ]
机构
[1] Kochi Med Sch, Dept Surg, Nanko Ku, Oko Cho, Kochi 7838505, Japan
[2] Kochi Med Sch, Dept Human Hlth & Med Sci, Kochi, Japan
关键词
C-reactive protein; Albumin; Neutrophil; Lymphocyte; Gastric cancer; Prognostic value; Survival; PREOPERATIVE RATIO; DOUBLE-BLIND; CLASSIFICATION; CHEMOTHERAPY; TRIAL;
D O I
10.1007/s00423-021-02356-w
中图分类号
R61 [外科手术学];
学科分类号
摘要
Purpose This study evaluated the prognostic value of C-reactive protein-to-albumin (CAR) and neutrophil-to-lymphocyte ratios (NLR) in conjunction with host-related factors in patients with unresectable advanced or recurrent gastric cancer. Methods A total of 411 patients with unresectable advanced gastric cancer were treated at Kochi Medical School between 2007 and 2019. Associations between clinicopathological parameters and systemic inflammatory and nutritional markers, including CAR and NLR, with overall survival were analyzed retrospectively. Results The optimal cut-off values of predicted median survival time were 0.096 (sensitivity, 74.9%; specificity, 42.5%) for CAR and 3.47 (sensitivity, 64.1%; specificity, 57.5%) for NLR, based on the results of receiver operating characteristic analysis. A weak significant positive correlation was identified between CAR and NLR (r = 0.388, P < 0.001). The median survival time was significantly higher in patients with intestinal-type than those with diffuse-type histology (18.3 months vs. 9.5 months; P = 0.001), CAR < 0.096 than those with CAR >= 0.096 (14.8 months vs. 9.9 months; P < 0.029), and those with NLR < 3.47 than NLR >= 3.47 (14.7 months vs. 8.8 months; P < 0.001). Multivariate survival analysis revealed that diffuse-type histology (hazard ratio (HR) 1.865; 95% confidence interval (CI) 1.397-2.490; P < 0.001)), 1 or more performance status (HR 11.510; 95% CI 7.941-16.683; P < 0.001), and NLR >= 3.47 (HR 1.341; 95% CI 1.174-1.769; P = 0.023) were significantly associated with independent predictors of worse prognosis. Conclusions High CAR and NLR are associated with poor survival in patients with unresectable and recurrent gastric cancer.
引用
收藏
页码:609 / 621
页数:13
相关论文
共 40 条
  • [1] Bang YJ, 2010, LANCET, V376, P1302
  • [2] Pathohistological classification systems in gastric cancer: Diagnostic relevance and prognostic value
    Berlth, Felix
    Bollschweiler, Elfriede
    Drebber, Uta
    Hoelscher, Arnulf H.
    Moenig, Stefan
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (19) : 5679 - 5684
  • [3] Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study
    Boku, Narikazu
    Yamamoto, Seiichiro
    Fukuda, Haruhiko
    Shirao, Kuniaki
    Doi, Toshihiko
    Sawaki, Akira
    Koizumi, Wasaburo
    Saito, Hiroshi
    Yamaguchi, Kensei
    Takiuchi, Hiroya
    Nasu, Junichiro
    Ohtsu, Atsushi
    [J]. LANCET ONCOLOGY, 2009, 10 (11) : 1063 - 1069
  • [4] Advanced gastric cancer: Current treatment landscape and future perspectives
    Digklia, Antonia
    Wagner, Anna Dorothea
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2016, 22 (08) : 2403 - 2414
  • [5] Cancer incidence and mortality among young adults aged 20-39 years worldwide in 2012: a population-based study
    Fidler, Miranda M.
    Gupta, Sumit
    Soerjomataram, Isabelle
    Ferlay, Jacques
    Steliarova-Foucher, Eva
    Bray, Freddie
    [J]. LANCET ONCOLOGY, 2017, 18 (12) : 1579 - 1589
  • [6] Japanese gastric cancer treatment guidelines 2018 (5th edition)
    Japanese Gastric Cancer Association
    [J]. GASTRIC CANCER, 2021, 24 (01) : 1 - 21
  • [7] Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
    Kang, Yoon-Koo
    Boku, Narikazu
    Satoh, Taroh
    Ryu, Min-Hee
    Chao, Yee
    Kato, Ken
    Chung, Hyun Cheol
    Chen, Jen-Shi
    Muro, Kei
    Kang, Won Ki
    Yeh, Kun-Huei
    Yoshikawa, Takaki
    Oh, Sang Cheul
    Bai, Li-Yuan
    Tamura, Takao
    Lee, Keun-Wook
    Hamamoto, Yasuo
    Kim, Jong Gwang
    Chin, Keisho
    Oh, Do-Youn
    Minashi, Keiko
    Cho, Jae Yong
    Tsuda, Masahiro
    Chen, Li-Tzong
    [J]. LANCET, 2017, 390 (10111) : 2461 - 2471
  • [8] S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial
    Koizumi, Wasaburo
    Narahara, Hiroyuki
    Hara, Takuo
    Takagane, Akinori
    Akiya, Toshikazu
    Takagi, Masakazu
    Miyashita, Kosei
    Nishizaki, Takashi
    Kobayashi, Osamu
    Takiyama, Wataru
    Toh, Yasushi
    Nagaie, Takashi
    Takagi, Seiichi
    Yamamura, Yoshitaka
    Yanaoka, Kimihiko
    Orita, Hiroyuki
    Takeuchi, Masahiro
    [J]. LANCET ONCOLOGY, 2008, 9 (03) : 215 - 221
  • [9] Elevated serum C-reactive protein level predicts a poor prognosis for recurrent gastric cancer
    Kong, Fanming
    Gao, Fangfang
    Chen, Jun
    Zheng, Rongxiu
    Liu, Honggen
    Li, Xiaojiang
    Yang, Peiying
    Liu, Geli
    Jia, Yingjie
    [J]. ONCOTARGET, 2016, 7 (34) : 55765 - 55770
  • [10] Nutrition update in gastric cancer surgery
    Kubota, Takeshi
    Shoda, Katsutoshi
    Konishi, Hirotaka
    Okamoto, Kazuma
    Otsuji, Eigo
    [J]. ANNALS OF GASTROENTEROLOGICAL SURGERY, 2020, 4 (04): : 360 - 368